December 2025 - TinyGems

WednesdayDec 31, 2025 9:00 am

New Gene Regulator Could Revive Immune System Response in Cancer Management

A gene regulator best known for its role in bone development is now emerging as a potential lever to restore immune responses in cancer patients who stop benefiting from immunotherapy. New findings from Taiwan suggest that blocking this regulator, RUNX2, may help worn-down immune cells regain their ability to fight tumors. National Taiwan University and National Taiwan University Hospital researchers identified RUNX2 as a key factor behind immune exhaustion in liver cancer. Their work points to RUNX2 as a driver of why immune checkpoint inhibitors, once effective, can lose their impact over time. Immune checkpoint inhibitors are designed to unleash…

FridayDec 26, 2025 9:00 am

Al Jazeera Unveils AI Tool to Support Their Teams

Al Jazeera is unveiling a new artificial intelligence platform aimed at supporting its teams as journalism becomes more data-heavy and faster paced. The initiative, called “The Core,” is being developed in partnership with Google Cloud and is designed to weave AI directly into the network’s daily news operations. The broadcaster says the project goes beyond a typical tech upgrade. Rather than treating AI as a background utility, Al Jazeera wants it to function as an active assistant throughout the news cycle. The system is intended to help journalists handle complex information, streamline internal processes, and free up time for reporting…

MondayDec 22, 2025 10:00 am

New Blood Test Reveals Whether Treatment is Working for Brain Cancer Patients

Researchers have revealed a new blood test that can determine whether brain cancer therapies are being effective. The diagnostic tool could guide glioblastoma physicians on whether to maintain current drug regimens, change medications, or halt interventions altogether. Adam Sonabend, a Northwestern Medicine neurosurgeon who co-directed a study published in Nature Communications, explained that using this test, treatment effectiveness becomes apparent after a single dose instead of months of waiting. This represents a major advancement for glioblastoma care. It could spare patients from continuing regimens that don't work while eliminating needless adverse reactions that diminish quality of life. Glioblastoma is typically lethal and claims most victims within 24 months. Since the tumors penetrate brain structures and make total surgical extraction incredibly difficult, only one…

WednesdayDec 17, 2025 10:00 am

Novel Biomarker Could Predict Resistance to Immunotherapy, Study Finds

Scientists at Northwestern Medicine have discovered a biological marker that predicts which cancer patients are more resistant to immunotherapy. Dubbed USP22, the marker also points to a potential treatment target for non-responders. Findings published in The Journal of Clinical Investigation have the potential to transform care for patients whose current options remain limited. Checkpoint blockade immunotherapy prevents harmful interactions between immune cells and cancer cells, keeping T-cells active so they can attack tumors. The approach has revolutionized cancer treatment over the past decade. However, despite early optimism about its potential to become a universal solution, immunotherapy only helps a small fraction of cancer patients. Earlier research showed that low levels of MHC-I proteins on tumor…

MondayDec 15, 2025 9:00 am

US Navy, Palantir Partner to Build AI Submarine

The U.S. Navy has partnered with AI firm Palantir on a $448 million effort to advance computational intelligence and machine automation throughout submarine production. This partnership aims to transform shipyard workflows using sophisticated analytics and prediction tools. Maritime Industrial Base Program leaders alongside Naval Sea Systems Command will direct the Shipbuilding Operating System initiative. The software will consolidate inputs from planning applications, historical records and operational reporting to reveal production slowdowns, enhance design processes and enable preventive problem-solving. Submarine manufacturers, submarine maintenance yards and essential parts providers will get first access, with warship initiatives adopting similar approaches after the approach’s…

WednesdayDec 10, 2025 10:00 am

Optimal Treatment Timing Could Boost Cancer Therapy Efficacy

Administering chemotherapy at specific times could significantly improve outcomes for brain cancer patients. Washington University in St. Louis researchers discovered that treatment timing plays a crucial role in how effectively glioblastoma patients respond to standard drug protocols. Funding came from NCI, Siteman Cancer Center, and National Institutes of Health, with the cancer center operating at WashU Medicine and Barnes-Jewish Hospital. Examining glioblastoma's resistance to treatment despite affecting hundreds of thousands annually, the findings were published in the Journal of Neuro-Oncology. While Temozolomide remains the go-to chemotherapy compound for this malignancy, many patients see limited benefits. Cancer cells typically activate MGMT,…

MondayDec 08, 2025 10:00 am

Study Proposes Overhaul of US Lung Cancer Screening Guidelines

A new analysis is calling for major changes to how the United States screens for lung cancer. Current rules, the study argues, leave out most people who eventually develop the disease. Researchers behind the study say the system used today is far too narrow and fails to capture the full range of Americans who end up at risk. The work, published in JAMA Network Open, examined nearly one thousand lung cancer cases treated at Northwestern Medicine over a five year span. Researchers set out to determine how many of those patients would have qualified for routine CT scans under the…

WednesdayDec 03, 2025 10:00 am

EV Expertise Fuels Successes in Chinese-Made Flying Cars

China's battery-car mastery is propelling its flying vehicle manufacturers ahead of global rivals. Expertise developed through years of electric vehicle production and unmanned aircraft development is giving domestic companies a distinct edge in the nascent aerial mobility market. Aridge, a division of XPeng's automotive business, operates a production facility in Guangzhou capable of assembling one vehicle every thirty minutes at peak capacity. Trial manufacturing launched last month with consumer deliveries planned for next year following more than 7,000 advance orders. Its modular system uses a lightweight six-rotor aircraft that ascends vertically and nests inside a wheeled ground vehicle called the…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Month: December 2025